CHANGES OF SYSTEMIC FIBRINOLYTIC AND HEMOSTATIC PARAMETERS DURING LOCAL FIBRINOLYSIS WITH TISSUE-PLASMINOGEN ACTIVATOR (RT-PA)

被引：0

作者：

KLEIN, P

ROTH, FJ

RIEGER, H

POPOVCENIC, S

机构：

[1] UNIV BONN,AGGERTALKLIN ENGELSKIRCHEN,W-5300 BONN,GERMANY

[2] UNIV BONN,INST EXPTL HAMATOL,W-5300 BONN,GERMANY

来源：

VASA-JOURNAL OF VASCULAR DISEASES | 1992年 / 21卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

During the local fibrinolysis with rt-PA (2.5 mg/h) systemic plasminogen and alpha 2-antiplasmin activities slightly decrease, but the fibrinolytic system is compensated during the whole treatment. The d-dimer plasma levels increase dependently on the mass of thrombus. Despite the administration of high doses of heparin during the fibrinolysis thrombin is formed, measured as thrombin-antithrombin III complex (TAT).

引用

页码：249 / 252

页数：4

共 50 条

[31] Pharmacologic partial salvage of a failing free flap with recombinant tissue plasminogen activator (rt-PA)
Atiyeh, BS
Fuleihan, NS
Musharafieh, RS
JOURNAL OF RECONSTRUCTIVE MICROSURGERY, 1999, 15 (08) : 585 - 590
[32] COMPLEMENT ACTIVATION BY THROMBOLYTIC AGENTS IN ACUTE MYOCARDIAL-INFARCTION - A COMPARISON BETWEEN STREPTOKINASE (SK) AND RECOMBINANT TISSUE-PLASMINOGEN ACTIVATOR (RT-PA)
GARDINALI, M
FRANGI, D
CUGNO, M
CONCIATO, L
CAFARO, C
SPONZILLI, C
AGOSTONI, A
CLINICAL RESEARCH, 1994, 42 (02): : A193 - A193
[33] FIBRINOLYSIS TREATMENT WITH RT-PA (RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR) IN SUDDEN HEARING-LOSS - HEMORHEOLOGIC AND THERAPEUTIC EFFECTS
HAGEN, R
LARYNGO-RHINO-OTOLOGIE, 1991, 70 (07) : 353 - 358
[34] FIBRINOLYTIC TREATMENT OF DEEP ILEOFEMORAL VENOUS THROMBOSIS WITH DIFFERENT DOSES OF RT-PA (RECOMBINANT TISSUE PLASMINOGEN-ACTIVATOR) - PILOT-STUDY
DODER, A
PILGER, E
OBERNOSTERER, A
DECRINIS, M
TISCHLER, R
LAFER, M
STARK, G
ASCHAUER, M
VASA-JOURNAL OF VASCULAR DISEASES, 1992, : 41 - 42
[35] LOCAL LYSIS TREATMENT WITH PLASMINOGEN-ACTIVATOR (RT-PA) FOR SPONTANEOUS INTRACEREBRAL HEMORRHAGE - INDICATION AND LIMITATIONS
SCHALLER, C
ROHDE, V
HASSLER, W
NERVENARZT, 1995, 66 (04): : 275 - 281
[36] APROTININ - AN ANTIDOTE FOR RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR (RT-PA) ACTIVE INVIVO
CLOZEL, JP
BANKEN, L
ROUX, S
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1990, 16 (02) : 507 - 510
[37] Intravenous Tissue Plasminogen Activator (rt-PA) in Anticoagulated Patients With Acute Ischemic Stroke: Safety and Outcomes
Barazangi, Nobl
Schmid, Kristin
Phan, Jackie
Bedenk, Ann
Rose, Jack
Tong, David
STROKE, 2010, 41 (04) : E307 - E307
[38] The Effect Of Intravenous Thrombolysis Using Recombinant Tissue Plasminogen Activator (rt-PA) For Acute Ischemic Stroke
Pan Shuming
Shen Sa
Dai Lihua
Li Haojun
Liu Ming
STROKE, 2011, 42 (03) : E126 - E126
[39] The effects of recombinant tissue-type plasminogen activator (rt-PA) on canine cadaver lung transplantation
Akasaka, S
Nishi, H
Aoe, M
Date, H
Andou, A
Shimizu, N
SURGERY TODAY-THE JAPANESE JOURNAL OF SURGERY, 1999, 29 (08): : 747 - 754
[40] Time Intervals of Symptomatic Intracereberal Hemorrhage (sICH) after Tissue Plasminogen Activator (rt-PA) Treatment
Chen, Patrick
Meyer, Brett
Rapp, Karen
Hemmen, Thomas
Modir, Royya
Agrawal, Kunal
Huisa-Garate, Branko
Hailey, Lovella
Attenhofer, Kevin
Lunagaryia, Abhishek
Selvan, Pradeep
Meyer, Dawn
NEUROLOGY, 2018, 90

← 1 2 3 4 5 →